Virginia L. Cunningham

Metrics to ‘green’ chemistry—which are the best?

A considerable amount has been written about the use of metrics to drive business, government and communities towards more sustainable practices. A number of metrics have also been proposed over the past 5–10 years to make chemists aware of the need to change the methods used for chemical syntheses and chemical processes. This paper explores several metrics commonly used by chemists and compares and contrasts these metrics with a new metric known as reaction mass efficiency. The paper also uses an economic analysis of four commercial pharmaceutical processes to understand the relationship between metrics and the most important cost drivers in these processes.

So you think your process is green, how do you know?—Using principles of sustainability to determine what is green–a corporate perspective

An approach to quantitatively and systematically evaluate synthetic organic reactions and processes is described. This sustainability-based approach allows chemists to clearly assess whether or not chemistries and chemical processes are ‘greener’. The results of this work indicate that close attention to effective use and reuse of solvents will result in the largest gains for reducing life cycle impacts in batch chemical operations.

Human health risk assessment from the presence of human pharmaceuticals in the aquatic environment

Assessments for potential impact to human health from environmental exposures were carried out for 44 active pharmaceutical ingredients (APIs) marketed by GlaxoSmithKline (GSK), representing approximately 22 general pharmacological classes exhibiting a broad spectrum of therapeutic activities. These assessments use the considerable amount of information available on the human pharmacology and toxicology of the APIs to develop acceptable daily intakes (ADIs) which are believed to be without pharmacological or toxicological effect. With the exception of the anti-cancer drugs and some antibiotics, the minimum dose producing the intended therapeutic effect was typically used as the point of departure for calculation of ADIs. The ADI values were used to generate predicted no effect concentrations from environmental exposure for human health (PNEC(HH)s) from drinking water or fish consumption. These PNECs were compared to predicted environmental concentrations (PECs) calculated using the regional assessment models PhATE for North America and GREAT-ER for Europe. Risk was characterized by calculating the ratio of the 90th percentile PECs to the PNEC(HH)s. For the APIs reported here, these ratios are less than one for all of the compounds, varying from 7x10(-2) to 6x10(-11), indicating that based upon currently available data, these compounds do not appear to pose an appreciable risk to human health from potential environmental exposure from drinking water and fish consumption.

Cradle-to-gate life cycle inventory and assessment of pharmaceutical compounds

Background, Goal and ScopeThe research presented here represents one part of GlaxoSmithKline’s (GSK) efforts to identify and improve the life cycle impact profile of pharmaceutical products. The main goal of this work was to identify and analyze the cradle-to-gate environmental impacts in the synthesis of a typical Active Pharmaceutical Ingredient (API). A cradle-to-gate life cycle assessment of a commercial pharmaceutical product is presented as a case study.MethodsLife cycle inventory data were obtained using a modular gate-to-gate methodology developed in partnership with North Carolina State University (NCSU) while the impact assessment was performed utilizing GSK’s sustainability metrics methodology.Results and DiscussionMajor contributors to the environmental footprint of a typical pharmaceutical product were identified. The results of this study indicate that solvent use accounts for a majority of the potential cradle-to-gate impacts associated with the manufacture of the commercial pharmaceutical product under study. If spent solvent is incinerated instead of recovered the life-cycle profile and impacts are considerably increased.ConclusionsThis case study provided GSK with key insights into the life-cycle impacts of pharmaceutical products. It also helped to establish a well-documented approach to using life cycle within GSK and fostered the development of a practical methodology that is applicable to strategic decision making, internal business processes and other processes and tools.

Consideration of exposure and species sensitivity of triclosan in the freshwater environment

ABSTRACT Triclosan (TCS) is a broad-spectrum antimicrobial used in consumer products including toothpaste and hand soap. After being used, TCS is washed or rinsed off and residuals that are not biodegraded or otherwise removed during wastewater treatment can enter the aquatic environment in wastewater effluents and sludges. The environmental exposure and toxicity of TCS has been the subject of various scientific and regulatory discussions in recent years. There have been a number of publications in the past 5 y reporting toxicity, fate and transport, and in-stream monitoring data as well as predictions from aquatic risk assessments. State-of-the-science probabilistic exposure models, including Geography-referenced Regional Exposure Assessment Tool for European Rivers (GREAT-ER) for European surface waters and Pharmaceutical Assessment and Transport Evalutation (PhATE™) for US surface waters, have been used to predict in-stream concentrations (PECs). These models take into account spatial and temporal variability in river flows and wastewater emissions based on empirically derived estimates of chemical removal in wastewater treatment and in receiving waters. These model simulations (based on realistic use levels of TCS) have been validated with river monitoring data in areas known to be receiving high wastewater loads. The results suggest that 90th percentile (low flow) TCS concentrations are less than 200 ng/L for the Aire–Calder catchment in the United Kingdom and between 250 ng/L (with in-stream removal) and 850 ng/L (without in-stream removal) for a range of US surface waters. To better identify the aquatic risk of TCS, a species sensitivity distribution (SSD) was constructed based on chronic toxicity values, either no observed effect concentrations (NOECs) or various percentile adverse effect concentrations (EC10–25 values) for 14 aquatic species including fish, invertebrates, macrophytes, and algae. The SSD approach is believed to represent a more realistic threshold of effect than a predicted no effect concentration (PNEC) based on the data from the single most sensitive species tested. The log-logistic SSD was used to estimate a PNEC, based on an HC5,50 (the concentration estimated to affect the survival, reproduction and/or growth of 5% of species with a 50% confidence interval). The PNEC for TCS was 1,550 ng/L. Comparing the SSD-based PNEC with the PECs derived from GREAT-ER and PhATE modeling to simulate in-river conditions in Europe and the United States, the PEC to PNEC ratios are less than unity suggesting risks to pelagic species are low even under the highest likely exposures which would occur immediately downstream of wastewater treatment plant (WWTP) discharge points. In-stream sorption, biodegradation, and photodegradation will further reduce pelagic exposures of TCS. Monitoring data in Europe and the United States corroborate the modeled PEC estimates and reductions in TCS concentrations with distance downstream of WWTP discharges. Environmental metabolites, bioaccumulation, biochemical responses including endocrine-related effects, and community level effects are far less well studied for this chemical but are addressed in the discussion. The aquatic risk assessment for TCS should be refined as additional information becomes available.

Exposure assessment of 17α-ethinylestradiol in surface waters of the United States and Europe†

An evaluation of measured and predicted concentrations of 17-ethinylestradiol in surface waters of the United States and Europe was conducted to develop expected long-term exposure concentrations for this compound. Measured environmental concentrations (MECs) in surface waters were identified from the literature. Predicted environmental concentrations (PECs) were generated for European and U.S. watersheds using the GREAT-ER and PhATE models, respectively. The majority of MECs are nondetect and generally consistent with model PECs and conservative mass balance calculations. However, the highest MECs are not consistent with concentrations derived from conservative (worst-case) mass balance estimates or model PECs. A review of analytical methods suggests that tandem or high-resolution mass spectrometry methods with extract cleanup result in lower detection limits and lower reported concentrations consistent with model predictions and bounding estimates. Based on model results using PhATE and GREAT-ER, the 90th-percentile low-flow PECs in surface water are approximately 0.2 and 0.3 ng/L for the United States and Europe, respectively. These levels represent conservative estimates of long-term exposure that can be used for risk assessment purposes. Our analysis also indicates that average concentrations are one to two orders of magnitude lower than these 90th-percentile estimates. Higher reported concentrations (e.g., greater than the 99th-percentile PEC of approximately 1 ng/L) could result from methodological problems or unusual environmental circumstances; however, such concentrations are not representative of levels generally found in the environment, warrant special scrutiny, and are not appropriate for use in risk assessments of long-term exposures.

Human health risk assessment of carbamazepine in surface waters of North America and Europe

A human health risk assessment was carried out for environmental exposures to carbamazepine (CBZ) and its major human metabolites, carbamazepine diol (CBZ-DiOH) and carbamazepine N-glucuronide (CBZ-N-Glu). Carbamazepine is an active pharmaceutical ingredient (API) used worldwide as a medicine for treating epileptic seizures and trigeminal neuralgia. Carbamazepine tends to be detected in surface water more frequently, and at relatively higher concentrations, than most other APIs. Predicted no effect levels (PNECs) for CBZ and its major human metabolites were developed for surface waters to be protective of human health from environmental exposures from drinking water and fish consumption. These PNECs were compared to both measured (MEC) and predicted (PEC) environmental concentrations for North America and Europe. PECs were calculated using the geo-referenced models PhATE for North America and GREAT-ER for Europe. The combined PNEC for drinking water and fish consumption for CBZ is 226,000ng/L. Ninetieth percentile MECs ranged from 150 to 220ng/L, while 90th percentile PECs ranged from 333 to 658ng/L. Calculated margins of safety (MOS) therefore range from 340 to 1500. MOS for the major metabolites are significantly higher. This assessment indicates that CBZ and its major metabolites have high MOS (>>1) and thus should have no appreciable risk to human health through environmental exposures based on available human data.

How do you select the “greenest” technology? Development of guidance for the pharmaceutical industry

There is widespread interest in government and industry in green chemistry and green technology. For truly “green” processes to be developed, scientists must take a concurrent, integrated approach that considers chemistry and technology. While it is vital to understand those things traditionally considered in technology selection such as operational, quality, and cost differences, it is equally vital to understand the associated environmental and safety issues that are inherent to the chosen technology. This is a major challenge and there is a clear need for guidance in this area. This paper proposes the concept of a “Clean/Green Technology Guide” as an expert system that would provide scientists and engineers with comparative environmental and safety performance information on available technologies for commonly performed unit operations in the pharmaceutical industry. At this stage, the framework has been developed to demonstrate the concept, using a metric set based on the concepts of sustainable development. This framework is used to evaluate the alternatives on a case-scenario basis, and will compare traditional and emerging technologies. A life-cycle approach is also used in the evaluation of the alternatives. This approach is illustrated by comparing batch, mini-, and microreactors.

Predicting concentrations of trace organic compounds in municipal wastewater treatment plant sludge and biosolids using the PhATE™ model.

This article presents the capability expansion of the PhATE™ (pharmaceutical assessment and transport evaluation) model to predict concentrations of trace organics in sludges and biosolids from municipal wastewater treatment plants (WWTPs). PhATE was originally developed as an empirical model to estimate potential concentrations of active pharmaceutical ingredients (APIs) in US surface and drinking waters that could result from patient use of medicines. However, many compounds, including pharmaceuticals, are not completely transformed in WWTPs and remain in biosolids that may be applied to land as a soil amendment. This practice leads to concerns about potential exposures of people who may come into contact with amended soils and also about potential effects to plants and animals living in or contacting such soils. The model estimates the mass of API in WWTP influent based on the population served, the API per capita use, and the potential loss of the compound associated with human use (e.g., metabolism). The mass of API on the treated biosolids is then estimated based on partitioning to primary and secondary solids, potential loss due to biodegradation in secondary treatment (e.g., activated sludge), and potential loss during sludge treatment (e.g., aerobic digestion, anaerobic digestion, composting). Simulations using 2 surrogate compounds show that predicted environmental concentrations (PECs) generated by PhATE are in very good agreement with measured concentrations, i.e., well within 1 order of magnitude. Model simulations were then carried out for 18 APIs representing a broad range of chemical and use characteristics. These simulations yielded 4 categories of results: 1) PECs are in good agreement with measured data for 9 compounds with high analytical detection frequencies, 2) PECs are greater than measured data for 3 compounds with high analytical detection frequencies, possibly as a result of as yet unidentified depletion mechanisms, 3) PECs are less than analytical reporting limits for 5 compounds with low analytical detection frequencies, and 4) the PEC is greater than the analytical method reporting limit for 1 compound with a low analytical detection frequency, possibly again as a result of insufficient depletion data. Overall, these results demonstrate that PhATE has the potential to be a very useful tool in the evaluation of APIs in biosolids. Possible applications include: prioritizing APIs for assessment even in the absence of analytical methods; evaluating sludge processing scenarios to explore potential mitigation approaches; using in risk assessments; and developing realistic nationwide concentrations, because PECs can be represented as a cumulative probability distribution. Finally, comparison of PECs to measured concentrations can also be used to identify the need for fate studies of compounds of interest in biosolids.

Landfill disposal of unused medicines reduces surface water releases

The pharmaceutical industry is conducting research to evaluate the pathways and fate of active pharmaceutical ingredients from the consumer to surface waters. One potential pathway identified by the researchers is the disposal of unused pharmaceutical products that are discarded by consumers in household trash and disposed of in municipal solid waste landfills. This study was designed to evaluate relative amounts of surface water exposures through the landfill disposal pathway compared to patient use and flushing of unused medicine pathways. The estimated releases to surface water of 24 example active pharmaceutical ingredients (APIs) in landfill leachate were calculated for 3 assumed disposal scenarios: 5%, 10%, and 15% of the total annual quantity of API sold is discarded and unused. The estimated releases from landfills to surface waters, after treatment of the leachate, were compared to the total amount of each example API that would be released to surface waters from publicly owned treatment works, generated by patient use and excretion. This study indicates that the disposal of unused medications in municipal solid waste landfills effectively eliminates the unused medicine contribution of APIs to surface waters; greater than 99.9% of APIs disposed of in a landfill are permanently retained.